SCHEMBL7206316

SCHEMBL7206316

CC(=O)c1ccc2c(c1)c(-c1ccc(O)cc1)cc1cc(O)ccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 3/20 0.51
ESR2 Q92731 5/20 0.44
ESR1 P03372 4/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
WEE1 P30291 1/20 0.39
HSD17B10 Q99714 1/20 0.38
MIF P14174 1/20 0.37
PKM P14618 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
HIPK2 Q9H2X6 2/20 0.36
CSNK2A1 P68400 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7205374 0.82 ESR2 (0.63) HSD17B1ESR2ESR1ALDH1A1MAPT
SCHEMBL7204491 0.79 MEN1 (0.50) ESR2ALDH1A1MAPTHPGD
SCHEMBL7205462 0.78 ESR2 (0.77) ESR2ESR1ALDH1A1MAPTHSD17B10
SCHEMBL9302158 0.75 ALDH1A1 (0.50) HSD17B1ESR2ESR1ALDH1A1MAPT
SCHEMBL15502049 0.73 MAPT (0.62) HSD17B1ALDH1A1MAPTHPGDMAOB
SCHEMBL10138245 0.72 SLC22A12 (0.55) HSD17B1
SCHEMBL1177919 0.71 KMT2A (0.58) HSD17B1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL4091247 0.71 HSD17B1 (0.81) HSD17B1ESR2ESR1MAPTMMP2
SCHEMBL31402830 0.70 CYP2A6 (0.66) HSD17B1ESR2ESR1ALDH1A1MAPT
SCHEMBL31402829 0.70 CYP2A6 (0.66) HSD17B1ESR2ESR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599921-B2 Antiproliferative agents against estrogen-dependent cancer cells dibenzothiopyran, dibenzopyran and phenanthrene derivatives NANODESIGN, INC. (CA) 2003-07-29 US disclosed
US-20020156077-A1 Non-steroidal estrogen receptor ligands PALOMA PHARMACEUTICALS, INC. 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156077-A1 Non-steroidal estrogen receptor ligands ESRRA, ESRRB, ESRRG HSD17B1 58/4885ESR2 4/4885ESR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.